Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Your confirmation email is on its way. Please check your inbox for further instructions.

Inari Medical (NARI) Stock Forecast & Price Target

Inari Medical logo
$49.24 -1.53 (-3.01%)
(As of 11/14/2024 ET)

Inari Medical - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
6
Buy
5

Based on 11 Wall Street analysts who have issued ratings for Inari Medical in the last 12 months, the stock has a consensus rating of "Hold." Out of the 11 analysts, 6 have given a hold rating, and 5 have given a buy rating for NARI.

Consensus Price Target

$58.89
19.60% Upside
According to the 11 analysts' twelve-month price targets for Inari Medical, the average price target is $58.89. The highest price target for NARI is $74.00, while the lowest price target for NARI is $47.00. The average price target represents a forecasted upside of 19.60% from the current price of $49.24.

NARI Analyst Ratings Over Time

TypeCurrent Forecast
11/16/23 to 11/15/24
1 Month Ago
10/17/23 to 10/16/24
3 Months Ago
8/18/23 to 8/17/24
1 Year Ago
11/16/22 to 11/16/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
4 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
3 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$58.89$57.44$61.29$82.00
Forecasted Upside19.60% Upside29.38% Upside24.67% Upside39.01% Upside
Consensus Rating
Hold
Hold
Moderate Buy
Moderate Buy

NARI Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NARI Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Inari Medical Stock vs. The Competition

TypeInari MedicalMedical CompaniesS&P 500
Consensus Rating Score
2.45
2.80
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside19.60% Upside19,889.00% Upside8.58% Upside
News Sentiment Rating
Positive News

See Recent NARI News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/29/2024Truist Financial
2 of 5 stars
 Boost TargetHold ➝ Hold$46.00 ➝ $50.00+4.69%
10/29/2024Canaccord Genuity Group
1 of 5 stars
 Boost TargetBuy ➝ Buy$71.00 ➝ $74.00+73.87%
10/29/2024Needham & Company LLC
2 of 5 stars
M. Matson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
10/29/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$50.00 ➝ $52.00+22.18%
10/29/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$66.00 ➝ $67.00+57.42%
9/17/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$50.00+13.38%
Crypto’s Hidden Gem: The missing piece no one’s talking about (Ad)

You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.

Click Here to get the full details about Crypto’s Hidden Gem
9/3/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Kratky
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
9/3/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$47.00+8.72%
8/9/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$68.00+39.57%
7/31/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$84.00 ➝ $65.00+39.16%
7/25/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Kaczor
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
8/3/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$83.00+28.15%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 03:28 AM ET.


NARI Forecast - Frequently Asked Questions

According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Inari Medical is $58.89, with a high forecast of $74.00 and a low forecast of $47.00.

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inari Medical in the last year. There are currently 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NARI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NARI, but not buy additional shares or sell existing shares.

According to analysts, Inari Medical's stock has a predicted upside of 19.60% based on their 12-month stock forecasts.

Over the previous 90 days, Inari Medical's stock had 1 upgrade by analysts.

Inari Medical has been rated by research analysts at Canaccord Genuity Group, Leerink Partners, Leerink Partnrs, Needham & Company LLC, Piper Sandler, Robert W. Baird, Stifel Nicolaus, and Truist Financial in the past 90 days.

Analysts like Inari Medical less than other "medical" companies. The consensus rating for Inari Medical is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how NARI compares to other companies.


This page (NASDAQ:NARI) was last updated on 11/15/2024 by MarketBeat.com Staff
From Our Partners